The bad news continues to roll in for Theranos, the Silicon Valley-based blood-testing company that was previously valued at $9 billion. Just a few years ago, the company’s wunderkind C.E.O. Elizabeth Holmes was the subject of glowing media profiles. Today, the company she founded is the subject of a criminal probe by the Justice Department, and is also being investigated by the Securities and Exchange Commission over allegations of fraud. Regulators are also considering banning Holmes from owning or running blood-testing labs for two years. How unique is a probe into a company like this? What do the investigations into Theranos say about deal making in Silicon Valley?